Comparison of the effect of pioglitazone and Gloranta on metabolic factors of patients with non-alcoholic fatty liver disease and type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250919067293N1

Enrollment

Registered

2025-09-29

Start date

2025-10-17

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes mellitus. Condition 2: Non-alcoholic fatty liver. Diabetes mellitus due to underlying condition Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Intervention group: 72 people with diabetes and non-alcoholic fatty liver disease were divided into two groups of 36 people: one group received pioglitazone 15 mg d

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 75 years with non-alcoholic fatty liver disease and type 2 diabetes No history of alcohol consumption (20 grams per day for women and 30 grams per day for men) No history of cardiovascular events in the past 3 months Not pregnant or breastfeeding; active cancer or history of cancer treatment in the past 2 years; body mass index above 40 kg/m2.

Exclusion criteria

Exclusion criteria: Active or chronic hepatitis; cirrhosis and biliary disease; heart failure, renal dysfunction (eGFR <45 ml/min/1.73 m2) during the study Taking medications associated with fatty liver nonsteroidal anti-inflammatory drugs (NSAIDs) (amiodarone, tamoxifen, sodium valproate, corticosteroids, methotrexate). Simultaneous use of both drugs, Glurenta and Empagliflozin

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: Measurement of liver enzymes at the beginning of the study before the start of the intervention and 6 months after the start of Glurenta or pioglitazone. Method of measurement: A blood sample.;Blood pressure. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: Blood pressure measuring device.;Body mass index of individuals. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: Scales and meters.;? LDL? HDL? Total cholesterol,Triglycerides. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.;Fatty liver. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: The amount of liver fat is determined by ultrasound and fibroscan and based on the interpretation of the radiologist.;(FBS? BS2hpp? Hba1c). Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.;Platelet. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.	—

Measure

Time frame

Liver enzymes. Timepoint: Measurement of liver enzymes at the beginning of the study before the start of the intervention and 6 months after the start of Glurenta or pioglitazone. Method of measurement: A blood sample.;Blood pressure. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: Blood pressure measuring device.;Body mass index of individuals. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: Scales and meters.;? LDL? HDL? Total cholesterol,Triglycerides. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.;Fatty liver. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: The amount of liver fat is determined by ultrasound and fibroscan and based on the interpretation of the radiologist.;(FBS? BS2hpp? Hba1c). Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.;Platelet. Timepoint: At the beginning of the study before the start of the intervention and 6 months after starting Glorenta or pioglitazone. Method of measurement: blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Bahrampour

Bagheiat-allah University of Medical Sciences

Nemesisgrace@googlemail.com+98 21 5517 3894

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026